$5.97
-0.39-6.13%
In chiusura: Nov 16, 4:00 PM EST
$6.48
0.518.54%
Post-mercato: 8:04 AM EST
The average analyst price target for AgomAb Therapeutics is $37.50, 478.7% above the current price. Of 7 analysts, 7 rate it Buy. Targets range from $28 to $60. The latest change came on Aug 25, 2026, when Piper Sandler initiated coverage of AgomAb Therapeutics with an Overweight rating and a $60 price target.
Price Target Range — 3 Quarters
Analyst Consensus — 7 Analysts
Rating Trend — Last 9 Months
